Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19

Affiliations

• ¹ University of Connecticut Health Outcomes, Policy, and Evidence Synthesis Group and Hartford Hospital Department of Research Administration, Hartford, Connecticut, School of Pharmacy, Storrs, Connecticut, and Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru (A.V.H.).
• ² University of Connecticut Health Outcomes, Policy, and Evidence Synthesis Group and Hartford Hospital Department of Research Administration, Hartford, Connecticut (Y.M.R.).
• ³ MedErgy HealthGroup, Yardley, Pennsylvania (V.P.).
• ⁴ Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru (J.J.B.).
• ⁵ University of Connecticut Health Outcomes, Policy, and Evidence Synthesis Group and Hartford Hospital Department of Research Administration, Hartford, Connecticut, and School of Pharmacy, Storrs, Connecticut (C.M.W.).